TNF Pharmaceuticals Soars 35% Amid Rebranding and MYMD-1® Trial Plans

Introduction

TNF Pharmaceuticals, Inc. EFFEC (NASDAQ: TNFA), formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing therapies that target tumor necrosis factor-alpha (TNF-α) to regulate the immuno-metabolic system. Headquartered in Baltimore, the company’s lead small-molecule candidate, MYMD-1®, is designed as an oral TNF-α inhibitor for age-related and autoimmune conditions, while its Supera-CBD platform addresses chronic pain, addiction, and epilepsy.

Corporate Structure

Since its founding in 2014, TNF Pharmaceuticals has operated with a team of 11–50 employees, utilizing expertise in clinical research, medicinal chemistry, and regulatory affairs. Mitchell Glass, M.D., serves as President and Chief Medical Officer, overseeing the clinical development of MYMD-1® and strategic initiatives related to immunology and age-related disease research.

TNF-α inhibitor by ANIRUDH

Recent Developments and News

In July 2024, the company rebranded from MyMD Pharmaceuticals to TNF Pharmaceuticals, Inc., and began trading under the ticker TNFA on July 24, 2024. This rebranding aligns with its focus on TNF-α modulation.
A Phase 2 study of MYMD-1® in sarcopenia, completed in 2023, indicated statistically significant improvements in muscle mass and strength among older adults. Following these results, TNF Pharmaceuticals announced plans to initiate mid-stage (Phase 2b) clinical trials of MYMD-1® in sarcopenia in the second half of 2025.
In June 2025, the company partnered with the DADA2 Foundation to launch a Compassionate Use study of its investigational oral TNF-α inhibitor in children with Deficiency of Adenosine Deaminase 2 (DADA2), a rare autoinflammatory disorder.

Financial and Strategic Aspects

On July 21, 2025, TNFA closed at $0.1185 per share, reflecting a 35.43% increase on a trading volume of 25.1 million shares. This increase follows the rebranding and upcoming trial milestones. In its Form 10-Q filed on May 15, 2025, the company reported investment in research and development, with sufficient cash and equivalents to fund planned mid-stage studies. A Form 8-K filed on June 6, 2025, provided updates on management’s strategic priorities, confirming no material changes to corporate governance or financial forecasts. The definitive proxy (DEFR14A) filed on May 19, 2025, outlined proposals for the 2025 annual meeting, including director elections and executive compensation.

Strategically, TNF Pharmaceuticals aims to differentiate MYMD-1® through its oral dosing profile, offering dose flexibility compared to injectable TNF inhibitors. The company’s dual-platform approach—combining MYMD-1® for chronic inflammation and Supera-CBD for pain and neurological applications—seeks to diversify its pipeline and address various therapeutic areas.

Market Position and Industry Context

The global TNF-α inhibitor market is dominated by injectable biologics such as adalimumab and etanercept, which together generated over $30 billion in sales in 2023. Currently, no oral TNF-α inhibitors are approved. TNF Pharmaceuticals occupies a niche position as an early entrant in the oral small-molecule segment, targeting patients and payers seeking non-injectable therapies. Competition includes oral Janus kinase inhibitors and emerging small-molecule immunomodulators, though none directly replicate the TNF-α regulatory approach proposed for MYMD-1®.

tl;dr

TNFA shares increased by 35.43% on July 21, 2025, in relation to the July 24, 2024 rebranding and the planned initiation of Phase 2b trials for MYMD-1® in sarcopenia. The company’s May 15, 2025, 10-Q confirmed sufficient funds to support clinical activities, and a June 2025 partnership with the DADA2 Foundation added a pediatric Compassionate Use program. Mid-stage trial enrollment is expected to begin in Q3 2025, with pivotal data anticipated in 2026.